CELESTODERM V OINTMENT

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Køb det nu

Produktets egenskaber Produktets egenskaber (SPC)
29-09-2020

Aktiv bestanddel:

BETAMETHASONE (BETAMETHASONE VALERATE)

Tilgængelig fra:

BAUSCH HEALTH, CANADA INC.

ATC-kode:

D07AC01

INN (International Name):

BETAMETHASONE

Dosering:

0.1%

Lægemiddelform:

OINTMENT

Sammensætning:

BETAMETHASONE (BETAMETHASONE VALERATE) 0.1%

Indgivelsesvej:

TOPICAL

Enheder i pakken:

450G

Recept type:

Prescription

Terapeutisk område:

ANTI-INFLAMMATORY AGENTS

Produkt oversigt:

Active ingredient group (AIG) number: 0106299001; AHFS:

Autorisation status:

APPROVED

Autorisation dato:

2014-10-10

Produktets egenskaber

                                PRESCRIBING INFORMATION
PR
CELESTODERM
® V
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.1%
PR
CELESTODERM
® V/2
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.05%
TOPICAL CORTICOSTEROID
September
29
,
2020
DATE OF
REVISION:
Control
#:
242776
H7L 4A8
Laval, Quebec
2150 St-Elzear
Blvd. West
,
BAUSCH HEALTH, CANADA INC.
_ _
_Pr_
_CELESTODERM _
_®_
_ V and CELESTODERM_
_®_
_ V/2 Prescribing Information Page 2 of 10_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS…………………………………………………......4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
............................................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
_ _
_Pr_
_CELESTODERM _
_®_
_ V and CELESTODERM_
_®_
_ V/2 Prescribing Information Page 3 of 10_ PR
CELESTODERM
® V
Betamethasone valerate cream USP
Betamethasone valerate ointment USP
0.1%
PR
CELESTODERM
® V/2
Betamethasone valerate cream USP
Betamethasone val
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Produktets egenskaber Produktets egenskaber fransk 29-09-2020

Søg underretninger relateret til dette produkt